A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)
Part of paid clinical trials in Fresno, California.
- Sponsor
- MediWound Ltd
- Study ID
- NCT06568627
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Venous Leg Ulcer (VLU)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- EscharEx (EX-03) — DRUGa sterile lyophilized powder containing a concentrate of proteolytic enzymes enriched in bromelain (anacaulase-bcdb). The powder and sterile water are mixed to form a gel prior to application on the wound area.
- Placebo (Gel vehicle) — DRUGA sterile powder containing excipients only (no proteolytic enzymes). The powder and sterile water are mixed to form a gel prior to application on the wound area
Study Details
The main objective of this study is: To assess the efficacy and safety of EscharEx (EX-03 5% formulation) compared to placebo control,in debridement and wound bed preparation of Venous Leg Ulcers (VLU).
Key Dates
- Start date
- Jun 1, 2025
- Status verified
- Mar 2026
- Primary completion
- Dec 31, 2026
- Completion
- Mar 31, 2027
Study Design
- Enrollment
- 216 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: EscharEx (EX-03)EX-03 is the code name of the third generation of EscharEx investigational medicinal product (IMP) formulation. A sterile lyophilized powder containing a concentrate of proteolytic enzymes enriched in bromelain (anacaulase-bcdb ), the active pharmaceutical ingredient (API), that is blended with excipients. EX-03 5% powder, should be diluted with Water for Injection (WFI) prior usage.
- Placebo Comparator: PlaceboPlacebo (Gel Vehicle, hydrogel) contains the same excipients as in EX-03, without the API. Placebo powder, should be diluted with Water for Injection (WFI) prior usage.
Primary Outcome Measure
Incidence of complete debridement, clinically (visually) assessed after each application [ Time Frame: up to 2 weeks ]
Central Contacts
- Yael Katz-levy, Ph.D.+972-546774149
- Aya Ben-Yaakov, Ph.D+972-508814005
Locations (14)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Limb Preservation Platform, Inc | Fresno | California | 93710 | Shawn Cazzell, DPM (PRINCIPAL_INVESTIGATOR) |
| Angel City Research,Inc | Los Angeles | California | 90010 | Felix Sigal, MD (PRINCIPAL_INVESTIGATOR) |
| Center for Clinical Research INC | San Francisco | California | 94115 | Alexander Reyzelman, DPM (PRINCIPAL_INVESTIGATOR) Mher Vartivarian, DPM (SUB_INVESTIGATOR) |
| ILD Research Center | Vista | California | 92081 | Dean Dean Vayser, MD (PRINCIPAL_INVESTIGATOR) |
| University of Miami | Miami | Florida | 33136 | Robert Kirsner, MD (PRINCIPAL_INVESTIGATOR) |
| Boston Medical Center | Boston | Massachusetts | 02118 | Elizabeth Sanders, MD (PRINCIPAL_INVESTIGATOR) |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | Jeremy Goverman, MD (PRINCIPAL_INVESTIGATOR) |
| Rutgers New Jersey Medical Center | Newark | New Jersey | 07103 | Alex Wong, MD (PRINCIPAL_INVESTIGATOR) |
| Northwell Health Comprehensive Wound Healing Center | Lake Success | New York | 11042 | - |
| NYU Langone Health Long Island - Research & Academic Center | Mineola | New York | 11501 | Scott Gorenstein, MD (PRINCIPAL_INVESTIGATOR) |
| Mount Sinai West | New York | New York | 10019 | Michael Michael Dudkiewicz, MD (PRINCIPAL_INVESTIGATOR) John Lantis, MD (SUB_INVESTIGATOR) Mary Bridge, MD (SUB_INVESTIGATOR) |
| Cutting Edge Research LLC., | Circleville | Ohio | 43113 | Brock Liden, MD (PRINCIPAL_INVESTIGATOR) |
| Clinical Trial Network Houston | Houston | Texas | 77074 | Ullabritt Larka, MD (PRINCIPAL_INVESTIGATOR) |
| Woundcentrics, LLC | San Antonio | Texas | 78251 | Marcus Gitterle, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Fresno, CA
Related Studies
- Trial to Evaluate Cyclical Topical Wound Oxygen Therapy in the Treatment of Chronic Venous Leg UlcersPHASE4 · Recruiting · AOTI Ltd. · New York, New York
- A Non-Randomized Open Label Clinical Trial Evaluating DermaBind TLPHASE4 · Recruiting · HealthTech Wound Care · DeLand, Florida
- EVALUATION OF THE EFFICACY AND TOLERANCE OF VASHE SOLUTION VERSUS SALINE SOLUTION IN THE TREATMENT OF VENOUS OR MIXED LEG ULCERS PRESENTING INFLAMMATORY SIGNS SUGGESTING HEAVY BACTERIAL LOADNot Yet Recruiting · Laboratoires URGO · New York, New York
- Evaluating Intact Fish Skin Graft and Standard of Care Versus Standard of Care Alone in Nonhealing Venous Leg UlcersPHASE4 · Recruiting · Kerecis Ltd. · Monroeville, Pennsylvania